Company Overview and News

 
Check out top 10 stocks which moved the most last week; HDIL registers 50% gain

2018-08-19 moneycontrol
The market ended a truncated week on a good note, as benchmark indices closed with strong gains. The Nifty ended the day at a record closing high, while the Sensex ended higher by almost 300 points. Having said that, it failed to hold 38,000-mark.
PAGEIND 500449 UBL 532978 533155 TTNQY JUBLFOOD 532478 FILATEX RAIN BIRLAPREC 532540 JBLWY 509488 526227 522105 PGDQY EXIDEIND 517354 HVLQY GRAPHITE 532827 500339 UBHOLDINGS UNBWY HOCL EXQDY BAJAJFINSV BATAINDIA HAVELLS TCS 500086 507458 500043

 
India's Bharat Petroleum Plans $3B Petchem Plant Near Mumbai

2018-03-28 rigzone
MUMBAI, March 28 (Reuters) - India's Bharat Petroleum Corporation Ltd (BPCL) plans to build a $3 billion petrochemical unit to serve the Mumbai region, a company official said, to profit from the country's expected surge in demand for petrochemicals as its economy expands.
HOCL BPCL 500547 BRQPY 500449

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...